Sponsor or institution

Clinical trials and research at Opus Genetics, Inc

• 4Clinical trials
• 4NIH research projects
• 1Country

Newest trials

All recruiting trials (4)

• Safety and tolerability of a single retina gene therapy for RDH12-related LCA

  This early-stage gene therapy test tries a one-time retinal injection of OPGx-RDH12 to see if it is safe and may help people with RDH12-related Leber congenital amaurosis.

  Recruiting Phase 1/2 Opus Genetics, Inc · Phoenix, Arizona and 3 other locations · NCT07681778

• OPGx-BEST1 subretinal gene therapy for Best vitelliform macular dystrophy and autosomal-recessive bestrophinopathy

  This trial will test whether a one-time subretinal gene therapy called OPGx-BEST1 is safe and can improve or stabilize vision in adults with Best vitelliform macular dystrophy (BVMD) or autosomal-recessive bestrophinopathy (ARB) in one eye.

  Recruiting at 4 sites Phase 1/2 Opus Genetics, Inc · Los Angeles, California and 4 other locations · NCT07185256

• Phentolamine eye drops for adults with reduced night vision after keratorefractive surgery

  This will test whether nightly phentolamine eye drops can improve low-light (mesopic) vision in adults who developed decreased vision after keratorefractive surgery.

  Recruiting at 20 sites Phase 3 Opus Genetics, Inc · Chandler, Arizona and 19 other locations · NCT07140783

• Gene therapy for inherited retinal degeneration caused by LCA5 mutations

  This study is testing a new gene therapy to see if it can help improve vision in people with inherited retinal degeneration caused by LCA5 gene mutations.

  Recruiting at 2 sites Phase 1/2 Opus Genetics, Inc · Philadelphia, Pennsylvania and 1 other locations · NCT05616793

NIH-funded research (4)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Gene therapy for NMNAT1-related Leber congenital amaurosis

  A gene therapy using an AAV9 vector to deliver NMNAT1 could potentially help young patients with NMNAT1-related retinal degeneration improve or protect vision.

  NIH research Opus Genetics INC. · Raleigh, United States · NIH-11409872

• Gene therapy candidate for RDH12-related Leber congenital amaurosis

  A gene therapy approach using an AAV8 vector to deliver RDH12 to retinal cells in people with RDH12-related LCA, aiming to protect vision.

  NIH research Opus Genetics INC. · Raleigh, United States · NIH-11405186

• One-vector gene therapy for dominant retinitis pigmentosa

  This gene therapy aims to lower harmful rhodopsin and replace it with a healthy copy to help people with autosomal-dominant retinitis pigmentosa caused by many RHO mutations.

  NIH research Opus Genetics INC. · Raleigh, United States · NIH-11187134

• Gene therapy for treating a common inherited eye disease.

  This study is testing a new gene therapy for people with autosomal-dominant retinitis pigmentosa, a genetic eye condition that causes vision loss, by using a special delivery method to fix the faulty gene and help improve their sight.

  NIH research Opus Genetics INC. · Raleigh, United States · NIH-10919095

Quick answers

How many clinical trials run by Opus Genetics, Inc are recruiting right now?

4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →